Company Encyclopedia
View More
name
LUYE PHARMA
02186.HK
Luye Pharma Group Ltd., together with its subsidiaries, develops, produces, markets, and sells pharmaceutical products in the People’s Republic of China, the United States, Europe, and internationally. The company offers Lipusu for ovarian cancer and carcinoma of ovary; CMNa, a chemical sensitizer for cancer radiotherapy; Boyounuo, an injection for the treatment of various types of cancers; and Xuezhikang, a lipid-regulating drug for the treatment of hypercholesterolaemia. It also provides Maitongna for cerebral edema swelling by trauma or surgery, and for venous reflux disorders; Beixi, an acarbose capsule for Type 2 diabetes; and Seroquel, Seroquel XR, Erzofri, Rivastigmine Multi-Day Transdermal Patch, and Rivastigmine. In addition, the company offers Rykindo, an injection for the treatment of schizophrenia; and Lutingnuo, a glutathione injection for toxicity and injuries caused by ionizing radiation.
1.450 T
02186.HKMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking22/48
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE2.86%C
    • Profit Margin6.44%B
    • Gross Margin67.83%A
  • Growth ScoreC
    • Revenue YoY-2.16%D
    • Net Profit YoY-48.40%D
    • Total Assets YoY19.96%A
    • Net Assets YoY19.64%A
  • Cash ScoreC
    • Cash Flow Margin1553.90%B
    • OCF YoY-2.16%D
  • Operating ScoreD
    • Turnover0.21D
  • Debt ScoreC
    • Gearing Ratio48.36%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Morning Trend | LUYE PHARMA experiences reduced volume fluctuations, is a structural repair signal coming?

    LUYE PHARMA (2186.HK) has recently been mainly fluctuating with reduced volume, and the MACD death cross has not yet reversed, intensifying the short-term bull-bear game in the market. The stock price hovers around the support zone, with weak intraday rebound actions occurring frequently. Main funds are primarily focused on low absorption, with low participation from trend-following investors. If there is a volume breakout in the consolidation area, upward momentum may be released. Conversely, if there is a lack of capital support, it will continue to consolidate at low levels. The technical structure still needs repair, and it is recommended that investors remain on the sidelines and flexibly follow up after a volume structural rebound signal. Currently, the sector's risk appetite is low, and changes in relevant policies and market sentiment have a significant impact. The overall rhythm is weak, and it is advisable to cautiously control positions. Pay attention to recent news and changes in trading volume to seize the structural repair window

    Technical Forecast·
    HK
    02186
    -0.99%
    Technical Forecast·
    HK
    02186
    -0.99%

    Luye Pharma Wins FDA IND Clearance for Next-Generation CNS Drug LY03017

    Luye Pharma Group Ltd. has received FDA clearance for its IND application for LY03017, a next-generation CNS drug. This approval allows the company to start clinical trials in the U.S. for treating Alzheimer’s disease psychosis, Parkinson’s disease psychosis, and negative symptoms of schizophrenia. The FDA has also exempted the single ascending dose trial in Phase I, allowing direct progression to multiple ascending dose and subsequent trials.

    Reuters·
    HK
    02186
    -0.99%
    Reuters·
    HK
    02186
    -0.99%

    Luye Pharma Gets U.S. FDA Nod to Start Trials for New CNS Drug

    Luye Pharma Gets U.S. FDA Nod to Start Trials for New CNS Drug

    marketscreener·
    HK
    02186
    -0.99%
    marketscreener·
    HK
    02186
    -0.99%

    Luye Pharma Says Approval Obtained For LY03017 For Clinical Trials In U.S.

    Luye Pharma Group Ltd :APPROVAL OBTAINED FOR GROUP'S NEW DRUG LY03017 FOR CLINICAL TRIALS IN U.S.

    Reuters·
    HK
    02186
    -0.99%
    Reuters·
    HK
    02186
    -0.99%

    Morning Trend | LUYE PHARMA (2186.HK) experiences low-volume fluctuations, with funds focusing on whether the bottom support can hold?

    LUYE PHARMA (2186.HK) experienced weak fluctuations yesterday, with scarce buying throughout the day and continuous capital outflow, leading to reduced trading activity. There are no new catalytic factors driving the market, and funds are mainly in a wait-and-see mode, with momentum concentrated at key support levels. The progress of innovative drugs has cooled off in the short term, and market institutions have reduced their positions. The MACD daily chart has just formed a death cross, putting pressure on the technical pattern, with volatility concentrated in the intraday trading volume. If the bottom support is breached, it may trigger technical selling pressure. Investors should pay attention to the rotation of sector themes and changes in intraday capital flow of the company to assess the next round of declines or stabilization turning points

    Technical Forecast·
    HK
    02186
    -0.99%
    Technical Forecast·
    HK
    02186
    -0.99%
    © 2025 Longbridge｜Disclaimer